Enantioselective Synthesis of β-(3-Hydroxypyrazol-1-yl) Ketones Using an Organocatalyzed Michael Addition Reaction
作者:Sanjib Gogoi、Cong-Gui Zhao、Derong Ding
DOI:10.1021/ol900538q
日期:2009.6.4
β-(3-Hydroxypyrazol-1-yl) ketones have been prepared in high yields and excellent enantioselectivities (94−98% ee) via a Michaeladdition reaction between 2-pyrazolin-5-ones and aliphatic acyclic α,β-unsaturated ketones using 9-epi-9-amino-9-deoxyquinine as the catalyst. These results account for the first example of an aza-Michael addition of the ambident 2-pyrazolin-5-one anion to a Michael acceptor.
Nitroolefins are converted into the corresponding saturated ketones or aldehydes in high yield by treatment with Raney nickel and sodium hypophosphite in aqueous ethanol at pH 5.
通过在pH 5的乙醇水溶液中用阮内镍和次磷酸钠处理,可以高产率将硝基烯烃转化为相应的饱和酮或醛。
Enantioselective Conjugate
Addition of N-Heterocycles to α,β-Unsaturated Ketones
Catalyzed by Chiral Primary Amines
作者:Wenhu Duan、Wei Wang、Guangshun Luo、Shilei Zhang
DOI:10.1055/s-0029-1216636
日期:——
A new organocatalytic enantioselectiveconjugateaddition reaction of nitrogen-centered heterocycles with α,β-unsaturated ketones has been developed. Promoted by a chiral cinchona alkaloid derived primary amine, the reaction affords the adducts in moderate to high enantioselectivities. primary amines - N-heterocycles - enones - conjugateaddition - catalysis
Visible-Light-Promoted Synthesis of 1,4-Dicarbonyl Compounds via Conjugate Addition of Aroyl Chlorides
作者:Chao-Ming Wang、Dan Song、Peng-Ju Xia、Jing Wang、Hao-Yue Xiang、Hua Yang
DOI:10.1002/asia.201701738
日期:2018.2.2
A facile visible‐light photocatalytic conjugate addition to prepare 1,4‐dicarbonyl compounds has been developed by employing readily available aroyl chlorides as aryl radical sources. This operationally simple method shows a broad scope with regard to both aroyl chlorides and Michael acceptors. As a result, a variety of 1,4‐diketones were efficiently synthesized in moderate to good yields.
The present invention provides a compound of formula (I):
wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.